HannuTMattilaLSiitonenA. Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis2005; 64: 594–598.
3.
KeatA. Reiter’s syndrome and reactive arthritis in perspective. N Engl J Med1983; 309: 1606–1615.
4.
CsonkaGW. The course of Reiter’s Syndrome. Br Med J1958; 1: 1088–1090.
5.
KeatACMainiRNNkwaziGC. Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J1978; 1: 605–607.
6.
RichEHookEWIIIAlarcónGS. Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthr Rheum1996; 39: 1172–1177.
7.
HamdulaySSGlynneSJKeatA. When is arthritis reactive?Postgrad Med J2006; 82: 446–453.
8.
SteinCMDavisP. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol1996; 23: 506–511.
9.
ClarkMRSolingerAMHochbergMC. Human immunodeficiency virus infection is not associated with Reiter’s syndrome. Data from three large cohort studies. Rheum Dis Clin North Am1992; 18: 267–276.
10.
MijiyawaMOniankitanOKhanMA. Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol2000; 12: 281–286.
11.
KeatACThomasBJTaylor-RobinsonD. Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. Ann Rheum Dis1980; 39: 431–437.
12.
MartinDHPollockSKuoC-C. Chlamydia trachomatis infections in men with Reiter’s syndrome. Ann Intern Med1984; 100: 207–213.
13.
KeatAThomasBDixeyJ. Chlamydia trachomatis and reactive arthritis: the missing link. Lancet1987; 1: 72–4.
14.
KousaMSaikkuPRichmondS. Frequent association of chlamydial infection with Reiter’s syndrome. Sex Transm Dis1978; 5: 57–61.
RosenthalLOlhagenBEkS. Aseptic arthritis after gonorrhoea. Ann Rheum Dis1980; 39: 141–146.
18.
LeirisaloMSkylvGKousaM. Follow-up study on patients with Reiter’s disease and reactive arthritis with special reference to HLA-B27. Arthr Rheum1982; 25: 249–259.
19.
KousaM. Clinical observations on Reiter’s disease with special reference to the venereal and non-venereal aetiology. Acta Derm Venereol1978; 58: 5–36.
20.
CsonkaGW. Clinical aspects of Reiter’s syndrome. Ann Rheum Dis1979; 38: 4–7.
21.
SchaeverbekeTRenaudinHVernhesJP. Ureaplasma urealyticum and reactive arthritis. Clin Rheumatol1995; 14: 252–252.
22.
HorowitzSHorowitzJTaylor-RobinsonD. Ureaplasma urealyticum in Reiter’s syndrome. J Rheumatol1994; 21: 877–882.
23.
SchumacherHRJrMaggeSCherianPV. Light and electron microscopic studies on the synovial membrane in Reiter’s syndrome: immunocytochemical identification of chlamydial antigen in patients with early disease. Arthr Rheum1988; 31: 937–946.
24.
Taylor-RobinsonDGilroyCBThomasBJ. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet1992; 340: 81–82.
25.
RahmanMUCheemaMASchumacherHR. Molecular evidence for the presence of chlamydia in the synovium of patients with Reiter’s syndrome. Arthr Rheum1992; 35: 521–529.
26.
BasSGriffaisRKveinTK. Amplification of plasmid and chromosome chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies. Arthr Rheum1995; 38: 1005–1013.
27.
BraniganPJGérardHCHudsonAP. Comparison of synovial tissue and synovial fluid as the source of nucleic acids for detection of Chlamydia trachomatis by polymerase chain reaction. Arthr Rheum1996; 39: 1740–1746.
28.
LiFBulbulRSchumacherHRJr. Molecular detection of bacterial DNA in venereal-associated arthritis. Arthr Rheum1996; 39: 950–958.
29.
NikkariSPuolakkainenMYli-KerttulaU. Ligase chain reaction in detection of chlamydia DNA in synovial fluid cells. Br J Rheumatol1997; 36: 763–765.
30.
VittecoqOSchaeverbekeTFavreS. Molecular diagnosis of Ureaplasma urealyticum in an immunocompetent patient with destructive reactive polyarthritis. Arthr Rheum1997; 40: 2084–2089.
31.
TullyJGRoseDLBasemanJB. Mycoplasma pneumoniae and Mycoplasma genitalium mixture in synovial fluid isolate. J Clin Microbiol1995; 33: 1851–1855.
32.
GérardHCBraniganPJSchumacherHRJr. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter’s syndrome are viable but show aberrant gene expression. J Rheumatol1998; 25: 734–742.
33.
RihlMKlosAKöhlerL. Reactive arthritis. Best Practice Res Clin Rheumatol2006; 20: 1119–1137.
34.
GerardHCWhittum-HudsonJACarterJD. The pathogenic role of Chlamydia in spondyloarthritis. Curr Opin Rheumatol2010; 22: 363–367.
35.
KeatACMainiRNPegrumGD. The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. QJM1979; 48: 323–342.
36.
CarterJD. Treating reactive arthritis: insights for the clinician. Ther Adv Musculoskel Dis2010; 2: 45–54.
37.
CsonkaGW. Long-term follow-up and prognosis of Reiter’s syndrome. Ann Rheum Dis1979; 38: 24–28.
38.
GoodAE. Reiter’s syndrome: long-term follow-up in relation to development of ankylosing spondylitis. Ann Rheum Dis1979; 38: 39–45.
39.
PopertAJGillAJLairdSM. A prospective study of Reiter’s syndrome. An interim report on the first 82 cases. Br J Vener Dis1964; 40: 160–165.
40.
HannuTNieminenMSSwanH. Cardiac findings of reactive arthritis: an observational echocardiographic study. Rheumatol Int2002; 21: 169–172.
41.
KonttinenYTBergrothVNordströmD. IgA nephropathy in reactive arthritis. J Rheumatol1987; 14: 1070–1071.
42.
KhanMA. Update on spondyloarthropathies. Ann Intern Med2002; 136: 896–907.
CombeBLandeweRLukasC. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis2007; 66: 34–45.
47.
van de HeijdeDLandewéR. Imaging in spondylitis. Curr Opin Rheumatol2005; 17: 413–417.
48.
BalintPVKaneDWilsonH. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis2002; 61: 905–910.
49.
NikkariSPuolakkainenMNärvänenA. Use of a peptide based enzyme immunoassay in diagnosis of Chlamydia trachomatis triggered reactive arthritis. J Rheumatol2001; 28: 2487–2493.
50.
FrydénABengtssonAFobergU. Early antibiotic treatment of reactive arthritis associated with enteric infections: clinical and serological study. Br Med J1990; 301: 1299–1302.
51.
BardinTEnelCCornelisF. Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthr Rheum1992; 35: 190–194.
52.
ToivanenAToivanenP. Epidemiological, clinical, and therapeutic aspects of reactive arthritis and ankylosing spondylitis. Curr Opin Rheumatol1995; 7: 279–283.
53.
CuellarMLEspinozaLR. Management of spondyloarthropathies. Curr Opin Rheumatol1996; 8: 288–295.
54.
Leirisalo-RepoM. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am1998; 24: 737–751.
55.
AnandarajahARitchlinCT. Treatment update on spondyloarthropathy. Curr Opin Rheumatol2005; 17: 247–256.
JuvakoskiTLassusA. A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter’s disease. Scand J Rheumatol1982; 11: 106–108.
58.
DougadosMNguyenMCaporalR. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol1994; 23: 243–248.
59.
Wienecke T and Gotzsche PC. Paracetamol versus non steroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No: CD003789.
60.
McGettiganPHenryD. Cardiovascular risk and inhibition of cyclooxygenase. JAMA2006; 296: 1633–1644.
61.
KearneyPMBaigentCGodwinJ. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ2006; 332: 1302–1302.
62.
RayWAVaras-LorenzoCChungCP. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes2009; 2: 155–163.
PalazziCOlivieriID'AmicoE. Management of reactive arthritis. Expert Opin Pharmacother2004; 5: 61–70.
66.
BlythTHunterJAStirlingA. Pain relief in the rheumatoid knee after steroid injection a single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. Br J Rheumatol1994; 33: 461–463.
67.
CanosoJJNaredoEAspiration and injection of joints and periarticular tissues and intralesional therapy. In: HochbergMCSilmanAJSmolenJSWeinblattME (eds). Rheumatology, 5th ed. Philadelphia: Mosby Elsevier, 2011. Section 4: Principles of management, vol. 66, pp.617–628.
68.
CalinA. Management of Reiter’s syndrome. Ann Rheum Dis1979; 38: 96–97.
69.
GünaydinIPereiraPLDaikelerT. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol2000; 27: 424–428.
70.
Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art No: CD000952.
71.
Cranney A, Welch V, Adachi J, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No: CD001983.
72.
Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No: CD001347.
73.
DougadosMvan der LindenSLeirisalo-RepoM. Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthr Rheum1995; 38: 618–627.
74.
CleggDORedaDJWeismanMH. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome): a Department Of Veterans Affairs Cooperative Study. Arthr Rheum1996; 39: 2021–2027.
75.
EgsmoseCHansenTMAndersenLS. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis1997; 56: 32–36.
76.
CleggDORedaDJAbdellatifM. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs Cooperative Study. Arthr Rheum1999; 42: 2325–2329.
77.
BraunJZochlingJBaraliakosX. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis2006; 65: 1147–1153.
78.
OwenETCohenML. Methotrexate in Reiter’s disease. Ann Rheum Dis1979; 38: 48–50.
79.
CalinA. A placebo controlled, crossover study of azathioprine in Reiter’s syndrome. Ann Rheum Dis1986; 45: 653–655.
80.
LipskyPEvan der HeijdeDMSt ClairEW. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med2000; 343: 1594–1602.
81.
BathonJMMartinRWFleischmannRM. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med2000; 343: 1586–1593.
82.
GenoveseMCBathonJMMartinRW. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum2002; 46: 1443–1450.
83.
ReimoldAM. New indications for treatment of chronic inflammation by TNF-(alpha) blockade. Am J Med Sci2003; 325: 75–92.
84.
BraunJBrantJListingJ. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet2002; 359: 1187–1193.
85.
GormanJDSackKEDavisJCJr. Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor α. N Engl J Med2002; 346: 1349–1356.
86.
BraunJSieperJ. Biological therapies in the spondyloarthritides – the current state. Rheumatology2004; 43: 1072–1084.
87.
van der HeijdeDKivitzASchiffMH. Efficacy and safety of adalimumab in ankylosing spondylitis: results of a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum2006; 54: 2136–2146.
88.
KavanaughATutuncuZCatalan-SanchezT. Update on anti-tumor necrosis factor therapy in spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol2006; 18: 347–353.
89.
MeasePJGoffeBSMetzJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet2000; 356: 385–390.
90.
AntoniCEKruegerGGde VlamK. Infliximab therapy improves symptoms and signs of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis2005; 64: 1150–1157.
91.
MeasePJGladmanDDRitchlinCT. Adalimumab for the treatment of moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum2005; 52: 3279–3289.
92.
Van der BoschFKruithofEBaetenD. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum2002; 46: 755–765.
93.
KruithofEDe RyckeLRothJ. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum2005; 52: 3898–3909.
94.
KeaneJGershonSWiseRP. Tuberculosis associated with infliximab, a tumour necrosis factor α-neutralising agent. N Engl J Med2001; 345: 1098–1104.
95.
BaetenDKruithofEVan den BoschF. Systemic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?Ann Rheum Dis2003; 62: 829–834.
96.
MayerAChatelusEWendlingD. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum2011; 63: 1274–1280.
97.
FlaggSDMeadorRHsiaE. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum2005; 53: 613–617.
98.
WechalekarMDRischmuellerMWhittleS. Prolonged remission of chronic reactive arthritis treated with three infusions of infliximab. J Clin Rheumatol2010; 16: 79–80.
99.
SchafranskiMD. Infliximab for reactive arthritis secondary to Chamydia trachomatis infection. Rheumatol Int2010; 30: 679–680.
100.
Kaipiainen-SeppänenONiinisaloHKorpilähdeT. Treatment of reactive arthritis with infliximab. Scand J Rheumatol2003; 32: 122–124.
101.
MeadorRJHsiaECKitumnuaypongT. Is etanercept (ENBREL) effective in the treatment of reactive and undifferentiated arthritis?Arthritis Rheum2001; 44: S348–S348.
102.
GaylisN. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J Rheumatol2003; 30: 407–411.
103.
CarterJDGerardHCHudsonAP. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis2008; 67: 1181–1183.
104.
NordströmDLindyOLauhioA. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int1998; 17: 175–180.
105.
LauhioALeirisalo-RepoMLähdevirtaJ. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to chlamydia arthritis. Arthr Rheum1991; 34: 6–14.
106.
SieperJFendlerCLaitkaS. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthr Rheum1999; 42: 1386–1396.
107.
Yli-KerttulaTLuukkainenRYli-KerttulaU. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis2000; 59: 565–570.
108.
KvienTKGastonJSHBardinT. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis2004; 63: 1113–1119.
109.
SmiejaMMacPhersonDWKeanW. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann Rheum Dis2001; 60: 1088–1094.
110.
WakefieldDMcCluskeyPVermaM. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthr Rheum1999; 42: 1894–1897.
111.
WollenhauptJHammerMPottHG. A double-blind, placebo-controlled comparison of 2 weeks versus 4 months treatment with doxycycline in chlamydia-induced reactive arthritis. Arthr Rheum1997; 40: S143–S143.
112.
PutschkyNPottH-GKuipersJG. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective double-blind trial. Ann Rheum Dis2006; 65: 1521–1524.
113.
Dreses-WerringloerUPadubrinIZeidlerH. Effects of azithromycin and rifampicin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother2001; 45: 3001–3008.
114.
CarterJDValerianoJVaseyFB. Doxycycline versus doxycycline and rifampicin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomised 9-month comparison. J Rheumatol2004; 31: 1973–1980.
115.
CarterJDEspinozaLRInmanRD. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: A double-blind, placebo-controlled, prospective trial. Arthritis Rheum2010; 62: 1298–1307.
116.
Leirisalo-RepoMPaimelaLJulkunenH. A 3-month, randomised, placebo-controlled study with combination antimicrobial therapy in acute reactive arthritis. Arthritis Rheum2001; 44: S91–S91.
117.
Yli-KerttulaTLuukkainenRYli-KerttulaU. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis2003; 62: 880–884.
118.
LaasilaKLaasonenLLeirisalo-RepoM. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis2003; 62: 655–658.
119.
PottHGWittenborgAJunge-HülsingG. Long-term antibiotic treatment in reactive arthritis. Lancet1988; 1: 245–256.
120.
BarberCEKimJInmanRD. Antibiotics for treatment of reactive arthritis: a systemic review and metaanalysis. J Rheumatol2013; 40: 916–928.
O’DuffyEKClunieGPRLuiD. Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic knee synovitis. Ann Rheum Dis1999; 58: 554–558.
123.
PavlicaLNikolicDMagicZ. Successful treatment of postvenereal reactive arthritis with synovectomy and 3 months' azithromycin. J Clin Rheumatol2005; 11: 257–263.
124.
ThiersBH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol1997; 37: S69–S71.
125.
LouthrenooW. Successful treatment of severe Reiter’s syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases. J Rheumatol1993; 20: 1243–1246.
126.
RosenbaumJTSmithJR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol2002; 20 28: S143–S145.
127.
BraunJBaraliakosXListingJ. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents. Arthritis Rheum2005; 52: 2447–2451.
128.
TheodossiadisPGMarkomichelakisNNSfikakisPP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina2007; 27: 399–413.
129.
Levy-ClarkeGReedGNussenblattR. Is anti-tumour necrosis factor (TNF) agents effective in reducing uveitis flares in patients with spondyloarthropathies?Nature Clin Practice Rheumatol2007; 3: 376–377.
130.
SmithGRobertsRHallC. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Br J Rheumatol1996; 35: 458–462.
131.
de WitWvan MourikIWiesenhaanPF. Prolonged maternal indomethacin therapy associated with oligohydramnios. Case reports. Br J Obstet Gynecol1988; 95: 303–305.
